Insider trade

Chair sold ~$1.93M of DXCM shares in the open market

Traded Jul 6, 2026 · Filed Jul 7, 2026

DexcomDXCM

~$1.93M
Reported value · 27K sh @ $72.00: 356K
Holds after · shares reported: +19.1%
stock since the trade · S&P 500 +1.7%, $72.38 → $86.23 on Oct 1

Why it stands out

Dexcom's Executive Chair sold $1.93M of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 6, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 7, 2026

Chair$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,926,432

Shares × reported transaction price

Timing vs results

67 days after results of Apr 30, 2026, 24 days before results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $72.38 on Jul 6, 2026, 32% above its 52-week low and 19% below its high, after a 1% rise over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $89.53 (Jul 28, 2025), 51% of the way up, from 251 adjusted closes. 30 trading days earlier: $71.44 on May 20, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.8%	+1.3%	-3.1%
30 days	+14.4%	+3.7%	+10.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000133
Filed / recorded: Jul 7, 2026, 8:09 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Kevin R Sayer
Relationship: Director, Officer
Officer title: Executive Chair
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jul 6, 2026
Transaction code: S
Shares / units: 26,756
Price per share: $72.00
Acquired / disposed: Disposed (D)
Shares owned after: 355,726
Ownership form: Direct
Amendment: No

Footnotes from the filing

On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Around the same time

Director sold ~$160K of Dexcom

Scheduled in advance2mo ago

Director sold ~$171K of Dexcom